Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexmarilimab + Doxorubicin in Metastatic Soft-tissue Sarcoma
NCT07460986Phase 2Recruiting
- Sponsor
- MEDSIR
- Start
- Aug 2026
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bexmarilimab in soft tissue sarcoma (STS), sponsored by MEDSIR. Started Aug 2026; status: recruiting.
02
Drugs
bexmarilimab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT07460986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07460986.